Minimising the Adverse Physiological Effects of Transportation on the Premature Infant (TRiPs)

November 26, 2018 updated by: University of Nottingham

Centralisation of neonatal intensive care has led to an increase in postnatal inter-hospital transfers within the first 72 hours of life. Studies have shown transported preterm infants have an increased risk of intraventricular haemorrhage compared to inborns. The cause is likely multi-factorial, however, during the transportation process infants are exposed to noxious stimuli (excessive noise, vibration and temperature fluctuations), which may result in microscopic brain injury. However, there is a paucity of evidence to evaluate the effect of noise and vibration exposure during transportation.

In this study the investigators aim to quantify the level of vibration and noise as experienced by a preterm infant during inter-hospital transportation in ground ambulance in the United Kingdom

Secondary aims of the study are to:

i) measure the physiological and biochemical changes that occur as a result of ambulance transportation (ii) quantify microscopic brain injury through measurement of urinary S100B and other biomarkers (iii) evaluate the development of intraventricular haemorrhage on cranial ultrasound iv) monitor vibration and sound exposure, using a prototype measuring system, during neonatal transport using both a manikin and a small cohort of neonatal patients.

v) evaluate vibration and sound exposure levels using an updated transportation system modified to reduce effects.

Study Overview

Detailed Description

There were 50 000 premature births in the United Kingdom (UK) and this number is increasing each year due to changes in demographics of the childbearing population with a trend towards increasing maternal age, increased uptake in fertility treatments and a greater number of medically induced deliveries. This has resulted in a greater risk of preterm delivery. Significant advances in neonatal intensive care have led to better survival rates with more preterm infants surviving at the extremes of gestational age. However, this is not without significant co-morbidity in terms of increased incidence of respiratory disease, cerebral palsy, learning difficulties and behavioural problems in surviving infants. The long term effect of impairment in cognitive functioning has led to an increased incidence of special education needs (one to one support, special schools), lower scores of cognitive ability (e.g. reading & maths), a higher rate of school failure and lower up take of higher education in early adulthood in these infants.

Due to the increasing preterm birth rate year strategies to reduce this level of morbidity are of great importance to public health care. In 2003, neonatal services were reorganised into managed clinical network leading to the development of hospitals of different specialist levels of care working together with the aim to improve provision of quality care and neonatal outcomes. Although this change in practice has led to an increase in survival, the level of neurodisability has remained the same. Furthermore, the number of neonatal inter-hospital has subsequently increased (10,000 in 2010 to 16,000 in 2016) with the necessity to move premature infants to higher level centres for on-going care but also the need to move infants due to lack of available cots at higher level centres.

Neonatal transport has been associated with significant morbidity in terms of severe intraventricular haemorrhage (IVH). A large study of 69 000 very low birth weight infants based in the USA showed infants who undergo inter-hospital transportation within the first 72 hours of life, a period when infants are most vulnerable to IVH, are 75% more likely to develop any IVH and 44% more likely to develop severe IVH compared to inborn non-transported infants. Severe IVH has been associated with both short and long term neurological morbidity and mortality. It has been estimated 50 to 80% of survivors with severe IVH develop cerebral palsy and 70% have cognitive impairment. Mild IVH, although not significantly associated with severe impairment, has been shown result in lower developmental scores at school age, with a higher percentage of infants requiring educational support compared to infants who never developed IVH.

Given the significant lifelong impact of severe IVH on premature infants, their families and society, current practice needs to be stratified to reduce the risk associated with transportation. The causation of this additional morbidity is unknown and likely to be multifactorial. However, studies that have accounted for risk factors known to be associated with IVH, such as, low birth weight and intubation using multivariable regression models have still found an association between transport and IVH, which raises the question whether the physical process of transportation itself contributes to the development of IVH.

During transportation infants are exposed to both excessive vibration and noise. Studies have shown in healthy adults excessive vibration is associated with adverse health effects, such as, fatigue, headaches, circulatory disturbance and neurological disorders. Studies have shown neonates are exposed to vibration levels during neonatal transport to be in the range of 0.4-5.6m/s2, which would be deemed extremely uncomfortable by International Standards Organization (ISO) 2631. However, a weakness of all these studies accessing vibration levels during transport is in the location of the vibration sensor during measurement, which is either placed on the mattress or incubator and therefore may not give a true reflection of the vibration exposure the neonate's head endures.

Currently, there is a paucity of evidence to evaluate the effect of vibration on neonates especially during transportation. Cerebral blood flow can be monitored via near infra-red spectrometry (NIRS), which is a real time and non-invasive technique. Soul et al demonstrated that continuous monitoring of regional cerebral oxygenation with NIRS can be correlated with changes in systemic blood pressure and provide insight into the fluctuating nature of cerebral pressure in preterm infants and hence identify infants at risk of cerebral pathology. NIRS monitoring during ambulance transfer would allow real time assessment of the cerebral perfusion during ambulance transfer. Additionally, simultaneous vibration and noise measurement will allow correlation of exposure levels with changes in cerebral perfusion.

In addition, exposure to excessive sound, like vibration, has been shown to have adverse effects in healthy adults and neonates. Excessive noise has been shown to increase heart rate (HR), increase blood pressure, increase respiratory rates (RR) and alter sleep cycles in both term and preterm infants. Premature infants have decreased autonomic self-regulatory mechanisms and are unable to adapt to loud noxious stimuli, which predisposes them to physiological instability. This instability can potentially result in fluctuations in cerebral blood flow, which could increase the risk of bleeds.

Although a small number of studies have documented vibration (although of the incubator) and noise exposure during transportation, none of the studies have correlated the level of exposure with physiological changes or biochemical markers of neurological injury. Correlation of vibration exposure as experienced by the neonatal head and noise exposure within the incubator will allow the investigators to plan interventional strategies aimed at reducing both vibration and noise exposure. Overall, by reducing these noxious stimuli the investigators aim to reduce both subtle neurological injury and IVH to improve long term neurodevelopmental outcomes.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
        • Recruiting
        • University Hospitals Nottingham NHS Trust
        • Principal Investigator:
          • Don Sharkey, MBBS PhD
        • Sub-Investigator:
          • Lara Shipley, MBChB(Hons)
        • Sub-Investigator:
          • Aarti Mistry, MBChB

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 4 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Neonatal patients

Description

Inclusion Criteria:

  • Infant < 32 weeks gestation (Phase 1) or any neonatal patient (Phase 2)
  • Less than 72 hours of age
  • With written maternal consent

Exclusion Criteria:

  • Lethal and/or major congenital abnormality known at study entry
  • No realistic prospect of survival
  • No informed consent
  • Maternal death

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Inborn
  • Infants born within Nottingham University hospitals
  • < 32 weeks gestational age
  • < 72 hours old
Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
Transported
- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vibration
Time Frame: An average of 90 minutes
Vibration exposure levels during ambulance journey or inborn measurement for period as experienced by the infant's head & incubator (m/s2)
An average of 90 minutes
Noise
Time Frame: An average of 90 minutes
Sound exposure levels during the ambulance journey or inpatient measurement period both inside and outside the incubator (dB)
An average of 90 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraventricular haemorrhage
Time Frame: Until discharge from hospital, on average 3-4 months after admission.
Development of intraventricular haemorrhage on cranial ultrasound scan, Scans will be taken pre and 24 hours post transfer for transported groups. Both transported and inborn infants will have their routine cranial ultrasound scan results documented on day 1, 3, 7 and d28 or discharge cranial ultrasound, whichever came first, from time of birth until discharge from hospital.
Until discharge from hospital, on average 3-4 months after admission.
Heart rate (beats per minute)
Time Frame: an average of 90 min
Heart rate will be measured either during the ambulance journey or inpatient measurement period including following journery undertaken in modified transport system
an average of 90 min
Pulse oximetery (oxygen saturation %)
Time Frame: An average of 90 min
Oxygen saturations will be measured either during the ambulance journey or inpatient measurement period including following journery undertaken in modified transport system
An average of 90 min
Respiratory rate (breaths per minute)
Time Frame: An average of 90 min
Respiratory rate will be measured every 15 minutes either during the ambulance journey or inpatient measurement period including following journery undertaken in modified transport system
An average of 90 min
Near infrared spectroscopy (regional oxygen saturations)
Time Frame: An average of 90 min
Regional oxygen saturations via NIRS will be measured either during the ambulance journey or inpatient measurement period including following journery undertaken in modified transport system
An average of 90 min
Urine biochemical measurements
Time Frame: 3 days
Urine will be collected within the first 24 hours, 48 hours and 72 hours following vibration and noise exposure in the ambulance. Inborn patients will have urine collected within the first 24, 48 and 72 hours following measurement period. Urine will be used to quantify level of S100B.
3 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Don Sharkey, MBBS, PhD, University of Nottingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2018

Primary Completion (Anticipated)

July 31, 2020

Study Completion (Anticipated)

July 31, 2020

Study Registration Dates

First Submitted

November 12, 2018

First Submitted That Met QC Criteria

November 26, 2018

First Posted (Actual)

November 27, 2018

Study Record Updates

Last Update Posted (Actual)

November 27, 2018

Last Update Submitted That Met QC Criteria

November 26, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injuries

Clinical Trials on Physiological changes to noise and vibration exposure

3
Subscribe